4.68
Abeona Therapeutics Inc stock is traded at $4.68, with a volume of 1.24M.
It is up +5.17% in the last 24 hours and down -10.69% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$4.45
Open:
$4.44
24h Volume:
1.24M
Relative Volume:
3.48
Market Cap:
$227.14M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-1.814
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
-6.21%
1M Performance:
-10.69%
6M Performance:
-24.88%
1Y Performance:
-37.43%
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ABEO
Abeona Therapeutics Inc
|
4.68 | 227.14M | 0 | -54.19M | -37.34M | -2.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-05-25 | Initiated | Oppenheimer | Outperform |
Jul-03-24 | Initiated | H.C. Wainwright | Buy |
May-30-24 | Initiated | Stifel | Buy |
Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Sep-18-20 | Initiated | B. Riley FBR | Buy |
Feb-10-20 | Initiated | SVB Leerink | Outperform |
Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
Jun-27-19 | Initiated | Mizuho | Buy |
Oct-12-18 | Initiated | Mizuho | Buy |
Jun-05-18 | Initiated | Seaport Global Securities | Buy |
Nov-08-17 | Initiated | SunTrust | Buy |
Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
Oct-10-17 | Initiated | Citigroup | Buy |
Oct-05-17 | Reiterated | Maxim Group | Buy |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Jul-18-17 | Reiterated | Maxim Group | Buy |
Jun-22-17 | Resumed | Jefferies | Buy |
Jan-06-17 | Initiated | Jefferies | Buy |
Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Breakeven On The Horizon For Abeona Therapeutics Inc. (NASDAQ:ABEO) - simplywall.st
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Abeona Therapeutics Expands Team with Strategic Stock Grants for Key New Talent - Stock Titan
Abeona Therapeutics CEO sells shares worth $119,500 - Investing.com India
Abeona Therapeutics CEO sells shares worth $119,500 By Investing.com - Investing.com Australia
Abeona Therapeutics (NASDAQ:ABEO) Upgraded by StockNews.com to Hold Rating - MarketBeat
What is Zacks Small Cap’s Estimate for ABEO Q3 Earnings? - Defense World
What is Zacks Small Cap’s Forecast for ABEO Q1 Earnings? - Defense World
Equities Analysts Set Expectations for ABEO Q1 Earnings - Defense World
Trend Tracker for (ABEO) - news.stocktradersdaily.com
What is HC Wainwright’s Forecast for ABEO Q1 Earnings? - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Given Buy Rating at HC Wainwright - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com - Defense World
Abeona Therapeutics: Positive Outlook Amid FDA Hopes - MSN
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2024 Earnings Call Transcript - Insider Monkey
Abeona planning potential US launch of pz-cel to treat RDEB - Epidermolysis Bullosa News
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
Abeona Therapeutics Reports 2024 Financial Results - TipRanks
Earnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beat - Investing.com India
Earnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beat By Investing.com - Investing.com UK
Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations - MSN
Oppenheimer maintains Abeona Therapeutics Outperform rating - Investing.com India
Abeona Therapeutics® Reports Full Year 2024 Financial - GlobeNewswire
Abeona Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ABEONA THERAPEUTICS INC. SEC 10-K Report - TradingView
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory - Bluefield Daily Telegraph
Abeona Strengthens to $98M Cash Position as FDA Decision for Pz-cel Approaches - StockTitan
(ABEO) On The My Stocks Page - news.stocktradersdaily.com
Abeona Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Abeona Therapeutics at Leerink’s Global Healthcare Conference: Launch Plans for PZcell - Investing.com Canada
Abeona Therapeutics (ABEO) Projected to Post Earnings on Monday - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated at Oppenheimer - Defense World
Oppenheimer Initiates Coverage of Abeona Therapeutics (ABEO) with Outperform Recommendation - MSN
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of Abeona Therapeutics (LSE:0H7R) with Outperform Recommendation - Nasdaq
Trading (ABEO) With Integrated Risk Controls - Stock Traders Daily
Oppenheimer sets Abeona stock Outperform with $16 target By Investing.com - Investing.com Canada
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire
When Abeona Therapeutics Takes the Stage: CEO's Upcoming Leerink Conference Presentation - StockTitan
Abeona Therapeutics announces new employee inducement grants - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
How Abeona Therapeutics Is Structuring Compensation to Attract New Talent - StockTitan
Abeona Therapeutics Insider Stock Sales Prove Timely As Market Valuation Descends To US$232m - Simply Wall St
StockNews.com Downgrades Abeona Therapeutics (NASDAQ:ABEO) to Sell - MarketBeat
How the (ABEO) price action is used to our Advantage - Stock Traders Daily
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Down 6.8% in January - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics’ (ABEO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt - openPR
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):